Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
OFIX's Cash to Debt is ranked higher than
95% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. OFIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OFIX' s 10-Year Cash to Debt Range
Min: 0.02  Med: 1.25 Max: No Debt
Current: No Debt
Equity to Asset 0.77
OFIX's Equity to Asset is ranked higher than
72% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. OFIX: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
OFIX' s 10-Year Equity to Asset Range
Min: 0.36  Med: 0.65 Max: 0.85
Current: 0.77
0.36
0.85
Interest Coverage No Debt
OFIX's Interest Coverage is ranked higher than
91% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. OFIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OFIX' s 10-Year Interest Coverage Range
Min: 0.62  Med: 9.05 Max: 9999.99
Current: No Debt
0.62
9999.99
F-Score: 7
Z-Score: 6.52
M-Score: -3.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 2.09
OFIX's Operating margin (%) is ranked lower than
51% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. OFIX: 2.09 )
Ranked among companies with meaningful Operating margin (%) only.
OFIX' s 10-Year Operating margin (%) Range
Min: -49.44  Med: 14.51 Max: 24.18
Current: 2.09
-49.44
24.18
Net-margin (%) -2.59
OFIX's Net-margin (%) is ranked lower than
57% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. OFIX: -2.59 )
Ranked among companies with meaningful Net-margin (%) only.
OFIX' s 10-Year Net-margin (%) Range
Min: -43.98  Med: 6.16 Max: 34.01
Current: -2.59
-43.98
34.01
ROE (%) -3.39
OFIX's ROE (%) is ranked lower than
58% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. OFIX: -3.39 )
Ranked among companies with meaningful ROE (%) only.
OFIX' s 10-Year ROE (%) Range
Min: -71.87  Med: 12.10 Max: 40.27
Current: -3.39
-71.87
40.27
ROA (%) -2.52
OFIX's ROA (%) is ranked lower than
54% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. OFIX: -2.52 )
Ranked among companies with meaningful ROA (%) only.
OFIX' s 10-Year ROA (%) Range
Min: -31.59  Med: 7.40 Max: 27.4
Current: -2.52
-31.59
27.4
ROC (Joel Greenblatt) (%) 4.49
OFIX's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. OFIX: 4.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OFIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -121.91  Med: 32.79 Max: 118.69
Current: 4.49
-121.91
118.69
Revenue Growth (3Y)(%) -3.50
OFIX's Revenue Growth (3Y)(%) is ranked lower than
67% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. OFIX: -3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OFIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.3  Med: 12.20 Max: 18.5
Current: -3.5
-12.3
18.5
EBITDA Growth (3Y)(%) 10.90
OFIX's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. OFIX: 10.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OFIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -53.7  Med: 11.40 Max: 63.2
Current: 10.9
-53.7
63.2
EPS Growth (3Y)(%) -39.20
OFIX's EPS Growth (3Y)(%) is ranked lower than
88% of the 176 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. OFIX: -39.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OFIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.5  Med: 14.70 Max: 140.5
Current: -39.2
-59.5
140.5
» OFIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

OFIX Guru Trades in Q3 2014

Paul Tudor Jones 18,323 sh (+96.51%)
Diamond Hill Capital 527,131 sh (+16.05%)
Chuck Royce 59,300 sh (unchged)
Mario Gabelli 97,625 sh (-0.51%)
Arnold Schneider 108,113 sh (-3.42%)
Jim Simons 50,783 sh (-55.36%)
» More
Q4 2014

OFIX Guru Trades in Q4 2014

Jim Simons 142,887 sh (+181.37%)
Paul Tudor Jones 21,920 sh (+19.63%)
Diamond Hill Capital 566,586 sh (+7.48%)
Mario Gabelli 96,625 sh (-1.02%)
Arnold Schneider 104,733 sh (-3.13%)
Chuck Royce 56,000 sh (-5.56%)
» More
Q1 2015

OFIX Guru Trades in Q1 2015

Chuck Royce 105,400 sh (+88.21%)
Diamond Hill Capital 689,591 sh (+21.71%)
Mario Gabelli 95,925 sh (-0.72%)
Arnold Schneider 102,213 sh (-2.41%)
Paul Tudor Jones 8,982 sh (-59.02%)
Jim Simons 43,824 sh (-69.33%)
» More
Q2 2015

OFIX Guru Trades in Q2 2015

Jim Simons 129,679 sh (+195.91%)
Diamond Hill Capital 777,051 sh (+12.68%)
Mario Gabelli 101,525 sh (+5.84%)
Chuck Royce 106,200 sh (+0.76%)
Arnold Schneider 80,988 sh (-20.77%)
Paul Tudor Jones 6,452 sh (-28.17%)
» More
» Details

Insider Trades

Latest Guru Trades with OFIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 33.11
OFIX's Forward P/E is ranked lower than
73% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.15 vs. OFIX: 33.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.39
OFIX's P/B is ranked higher than
57% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. OFIX: 2.39 )
Ranked among companies with meaningful P/B only.
OFIX' s 10-Year P/B Range
Min: 0.77  Med: 1.98 Max: 2.73
Current: 2.39
0.77
2.73
P/S 1.81
OFIX's P/S is ranked higher than
63% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. OFIX: 1.81 )
Ranked among companies with meaningful P/S only.
OFIX' s 10-Year P/S Range
Min: 0.31  Med: 1.50 Max: 2.58
Current: 1.81
0.31
2.58
PFCF 43.76
OFIX's PFCF is ranked lower than
68% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 32.61 vs. OFIX: 43.76 )
Ranked among companies with meaningful PFCF only.
OFIX' s 10-Year PFCF Range
Min: 6.45  Med: 18.87 Max: 654.78
Current: 43.76
6.45
654.78
POCF 17.03
OFIX's POCF is ranked higher than
65% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 21.13 vs. OFIX: 17.03 )
Ranked among companies with meaningful POCF only.
OFIX' s 10-Year POCF Range
Min: 5.7  Med: 11.86 Max: 268.5
Current: 17.03
5.7
268.5
EV-to-EBIT 74.57
OFIX's EV-to-EBIT is ranked lower than
91% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 21.01 vs. OFIX: 74.57 )
Ranked among companies with meaningful EV-to-EBIT only.
OFIX' s 10-Year EV-to-EBIT Range
Min: -44.8  Med: 12.80 Max: 186.8
Current: 74.57
-44.8
186.8
Shiller P/E 90.15
OFIX's Shiller P/E is ranked lower than
86% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 30.83 vs. OFIX: 90.15 )
Ranked among companies with meaningful Shiller P/E only.
OFIX' s 10-Year Shiller P/E Range
Min: 11.19  Med: 21.55 Max: 92.75
Current: 90.15
11.19
92.75
Current Ratio 3.62
OFIX's Current Ratio is ranked higher than
64% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. OFIX: 3.62 )
Ranked among companies with meaningful Current Ratio only.
OFIX' s 10-Year Current Ratio Range
Min: 1.56  Med: 3.52 Max: 5.24
Current: 3.62
1.56
5.24
Quick Ratio 2.71
OFIX's Quick Ratio is ranked higher than
63% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. OFIX: 2.71 )
Ranked among companies with meaningful Quick Ratio only.
OFIX' s 10-Year Quick Ratio Range
Min: 1.13  Med: 2.58 Max: 3.82
Current: 2.71
1.13
3.82
Days Inventory 258.02
OFIX's Days Inventory is ranked lower than
79% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 130.22 vs. OFIX: 258.02 )
Ranked among companies with meaningful Days Inventory only.
OFIX' s 10-Year Days Inventory Range
Min: 143.21  Med: 201.26 Max: 317.36
Current: 258.02
143.21
317.36
Days Sales Outstanding 54.34
OFIX's Days Sales Outstanding is ranked higher than
73% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.40 vs. OFIX: 54.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
OFIX' s 10-Year Days Sales Outstanding Range
Min: 55.67  Med: 99.79 Max: 137.49
Current: 54.34
55.67
137.49

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.99
OFIX's Price/Net Current Asset Value is ranked higher than
61% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 6.85 vs. OFIX: 4.99 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OFIX' s 10-Year Price/Net Current Asset Value Range
Min: 2.2  Med: 5.04 Max: 235
Current: 4.99
2.2
235
Price/Tangible Book 3.01
OFIX's Price/Tangible Book is ranked higher than
61% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.09 vs. OFIX: 3.01 )
Ranked among companies with meaningful Price/Tangible Book only.
OFIX' s 10-Year Price/Tangible Book Range
Min: 1.48  Med: 4.59 Max: 111.32
Current: 3.01
1.48
111.32
Price/Projected FCF 1.67
OFIX's Price/Projected FCF is ranked higher than
63% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. OFIX: 1.67 )
Ranked among companies with meaningful Price/Projected FCF only.
OFIX' s 10-Year Price/Projected FCF Range
Min: 0.55  Med: 1.21 Max: 3.42
Current: 1.67
0.55
3.42
Price/Median PS Value 1.22
OFIX's Price/Median PS Value is ranked lower than
60% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. OFIX: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
OFIX' s 10-Year Price/Median PS Value Range
Min: 0.34  Med: 1.18 Max: 2.48
Current: 1.22
0.34
2.48
Earnings Yield (Greenblatt) (%) 1.27
OFIX's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. OFIX: 1.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OFIX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 6.00 Max: 13.8
Current: 1.27
0.5
13.8
Forward Rate of Return (Yacktman) (%) -39.29
OFIX's Forward Rate of Return (Yacktman) (%) is ranked lower than
97% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 4.59 vs. OFIX: -39.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OFIX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -42.5  Med: 4.40 Max: 41.9
Current: -39.29
-42.5
41.9

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 394 406 418
EPS($) 0.85 1.15 1.45
EPS without NRI($) 0.85 1.15 1.45

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:OFX.Germany,
Orthofix International NV was formed on October 19, 1987 under the laws of the Netherlands Antilles. The Company is a diversified, medical device company engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical devices used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, and external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. The Company has administrative and training facilities in the United States, Brazil, the United Kingdom, France, Germany, Puerto Rico and Italy and manufacturing facilities in the U.S. and Italy. The Company directly distributes its products in the U.S., the United Kingdom, Italy, Germany, France, Belgium, Brazil, Australia, and Puerto Rico. The Company manages its business by its four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation, Spine Fixation. The BioStim SBU manufactures, distributes, and provides support services for a portfolio of devices for enhancing bone fusion that utilize the Company's patented pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics SBU provides a portfolio of regenerative products that allow physicians to successfully treat various spinal and orthopedic conditions. This SBU specializes in the marketing of the Company's regeneration tissue forms. Biologics distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, mainly in the U.S. The Company's partnership with MTF allows it to exclusively market its Trinity Evolution and Trinity Elitetissue forms for musculoskeletal defects to enhance bone fusion. The Extremity Fixation SBU offers products that allow physicians to successfully treat various orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company's orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. The Spine
» More Articles for OFIX

Headlines

Articles On GuruFocus.com
Three Growing Companies Worth a Second Look Oct 09 2013 
Weekly CEO Buys Highlight: MOSY, PMT, APA, CUBI, OFIX May 26 2013 
Weekly 3-Year Low Highlights: SBY, PER, OFIX, EDG May 14 2013 
Orthofix International N.V. Reports Operating Results (10-K) Mar 03 2011 
Orthofix International N.V. (OFIX) CEO Alan Milinazzo buys 1,100 Shares Nov 09 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Oct 28 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Jul 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Apr 29 2010 
Orthofix International N.V. Reports Operating Results (10-Q) Nov 06 2009 
Orthofix International Announces Record Revenue in 2nd Quarter 2009 Jul 30 2009 

More From Other Websites
Orthofix International (OFIX): Strong Industry, Solid Earnings Estimate Revisions Aug 18 2015
ORTHOFIX INTERNATIONAL N V Financials Aug 12 2015
Can The Uptrend Continue for Orthofix (OFIX)? Aug 12 2015
Edited Transcript of OFIX earnings conference call or presentation 4-Aug-15 8:30pm GMT Aug 04 2015
Orthofix posts 2Q profit Aug 04 2015
Orthofix posts 2Q profit Aug 04 2015
Orthofix International NV Earnings Call scheduled for 4:30 pm ET today Aug 04 2015
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2015
Orthofix International Reports Second Quarter 2015 Financial Results Aug 04 2015
Q2 2015 Orthofix International NV Earnings Release - After Market Close Aug 04 2015
Orthofix International Schedules Second Quarter 2015 Earnings Release and Conference Call for August... Jul 24 2015
Coverage initiated on Orthofix by Sidoti Jul 10 2015
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Jun 25 2015
Orthofix Announces the Addition of Lilly Marks to Board of Directors Jun 25 2015
ORTHOFIX INTERNATIONAL N V Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 18 2015
5 Stocks Insiders Love Right Now Jun 10 2015
Insider Buying Still Strong as Market Volatility Spikes Jun 06 2015
Orthofix International to Participate in the Jefferies 2015 Global Healthcare Conference May 26 2015
Orthofix International NV Earnings Call scheduled for 4:30 pm ET today May 18 2015
Orthofix reports 1Q loss May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK